First Validated Bioanalytical Method for Corynantheidine Kratom Alkaloid

Why it matters

Corynantheidine, a minor kratom alkaloid with opioid antagonist properties, finally has a validated measurement method — enabling research into how this understudied compound shapes kratom's overall pharmacology.

The big picture

Kratom's pharmacology is far more complex than just mitragynine and 7-HMG. Alkaloids like corynantheidine that act as opioid antagonists may modulate kratom's opioid effects and contribute to its safety profile — and this new tool unlocks deeper research into that possibility.

Key findings

• • First validated UPLC-MS/MS method to quantify corynantheidine in rat plasma, requiring only a 25 µL sample
• • Corynantheidine showed 49.9% oral bioavailability in rats — nearly half of an oral dose reaches systemic circulation
• • The alkaloid was detected in brain tissue (corpus callosum and hippocampus), confirming blood-brain barrier penetration
• • Acts as a functional opioid antagonist at mu-opioid receptors, potentially modulating the effects of other kratom alkaloids

Bottom line

Preclinical pharmacokinetic study in male Sprague Dawley rats using IV and oral dosing (2.5 and 20 mg/kg); University of Florida researchers; published in J Pharm Biomed Anal (2020).